Scalper1 News
Morgan Stanley analyst Matthew Harrison downgraded Gilead Sciences (GILD) while upgrading Alexion Pharmaceuticals (ALXN) and Vertex Pharmaceuticals (VRTX), based on where he sees near-term catalysts in the current volatile market. Harrison maintained his price target of 127 on Gilead, but lowered his rating to equal-weight from overweight based on “relative attractiveness” to the other two stocks. Harrison wrote in a research note that while it’s Scalper1 News
Scalper1 News